Search

Your search keyword '"Barbarot S"' showing total 1,348 results
Start Over Author "Barbarot S"
1,348 results on '"Barbarot S"'

204. Dermatological manifestations of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis ( POIKTMP ): a case series of 28 patients

Author

Chasseuil, E., primary, McGrath, J.A., additional, Seo, A., additional, Balguerie, X., additional, Bodak, N., additional, Chasseuil, H., additional, Denis‐Musquer, M., additional, Goldenberg, A., additional, Goussot, R., additional, Irvine, A.D., additional, Khumalo, N.P., additional, King, M.C., additional, Küry, S., additional, Lipsker, D., additional, Mallet, S., additional, Mayosi, B.M., additional, Nanda, A., additional, Puzenat, E., additional, Salort‐Campana, E., additional, Sidbury, R., additional, Shimamura, A., additional, Bézieau, S., additional, Mercier, S., additional, and Barbarot, S., additional

Published
2019
Full Text
View/download PDF

205. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Author

Vestergaard, C., primary, Wollenberg, A., additional, Barbarot, S., additional, Christen‐Zaech, S., additional, Deleuran, M., additional, Spuls, P., additional, Flohr, C., additional, Trzeciak, M., additional, von Kobyletzki, L., additional, Seneschal, J., additional, Paul, C., additional, Bieber, T., additional, Werfel, T., additional, Fölster‐Holst, R., additional, Darsow, U., additional, Gieler, U., additional, Svensson, Å., additional, Cork, M., additional, Stalder, J.‐F., additional, De Raeve, L., additional, Kunz, B., additional, Simon, D., additional, Chernyshov, P., additional, Hijnen, D., additional, Gelmetti, C., additional, Ring, J., additional, Taieb, A., additional, de Bruin‐Weller, M., additional, and Thyssen, J.P., additional

Published
2019
Full Text
View/download PDF

206. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

Author

Silverberg, J.I., primary, Simpson, E.L., additional, Ardeleanu, M., additional, Thaçi, D., additional, Barbarot, S., additional, Bagel, J., additional, Chen, Z., additional, Eckert, L., additional, Chao, J., additional, Korotzer, A., additional, Rizova, E., additional, Rossi, A.B., additional, Lu, Y., additional, Graham, N.M.H., additional, Hultsch, T., additional, Pirozzi, G., additional, and Akinlade, B., additional

Published
2019
Full Text
View/download PDF

215. Manifestations dermatologiques de la poïkilodermie héréditaire fibrosante due à des mutations du gène FAMB111B : une série de 28 cas

Author

Chasseuil, E., primary, McGrath, J., additional, Seo, A., additional, Bodak, N., additional, Chasseuil, H., additional, Denis-Musquer, M., additional, Goldenberg, A., additional, Goussot, R., additional, Irvine, A., additional, Khumalo, N., additional, King, M.-C., additional, Küry, S., additional, Lipsker, D., additional, Mayosi, B., additional, Puzenat, E., additional, Salort-Compana, E., additional, Bézieau, S., additional, Mercier, S., additional, and Barbarot, S., additional

Published
2018
Full Text
View/download PDF

221. Sensibilité de l’évaluation globale par l’investigateur pour la détection des bénéfices cliniques associés au traitement de la dermatite atopique : analyse post-hoc des études LIBERTY AD SOLO

Author

Silverberg, J.I., primary, Simpson, E.L., additional, Thaçi, D., additional, Barbarot, S., additional, Bagel, J., additional, Chao, J., additional, Chen, Z., additional, Plaum, S., additional, Ardeleanu, M., additional, and Korotzer, A., additional

Published
2018
Full Text
View/download PDF

222. Hémangiomes infantiles traités par propranolol oral à > 3 mg/kg/j en raison d’une résistance à la dose usuelle de 3 mg/kg/j : étude nationale rétrospective

Author

Denos, C., primary, Barbarot, S., additional, Boccara, O., additional, Gagey Caron, V., additional, Maruani, A., additional, Miquel, J., additional, Droitcourt, C., additional, Bigorre, M., additional, Martin, L., additional, Léauté Labrèze, C., additional, Mazereeuw Hautier, J., additional, and Dreyfus, I., additional

Published
2018
Full Text
View/download PDF

223. Étude rétrospective du taux de maintien des biothérapies dans le psoriasis de l’enfant

Author

Phan, C., primary, Beauchet, A., additional, Bursztejn, A.C., additional, Severino-Freire, M., additional, Barbarot, S., additional, Girard, C., additional, Lasek, A., additional, Reguiai, Z., additional, Droitcourt, C., additional, Perrussel, M., additional, Abasq, C., additional, Brenaut, E., additional, Mallet, S., additional, Bourrat, E., additional, Hadj-Rabia, S., additional, Chaby, G., additional, Maruani, A., additional, Phan, A., additional, Jullien, D., additional, Plantain, P., additional, Piram, M., additional, Kupper, I., additional, Fougerousse, A.C., additional, Maccari, F., additional, Barthelemy, H., additional, Martin, L., additional, Lons-Danic, D., additional, Beylot-Barry, M., additional, Quiles-Tsimaratos, N., additional, Pallure, V., additional, Bouilly-Auvray, D., additional, Mery-Bossard, L., additional, Aubin, F., additional, and Mahé, E., additional

Published
2018
Full Text
View/download PDF

224. Efficacité et tolérance du dupilumab dans le traitement de la dermatite atopique de l’adulte : premières données d’une cohorte rétrospective multicentrique française

Author

Faiz, S., primary, Giovannelli, J., additional, Podevin, C., additional, Nosbaum, A., additional, Jachiet, M., additional, Bouaziz, J.-D., additional, Reguiai, Z., additional, Arnault, J.-P., additional, Tetart, F., additional, Duval-Modeste, A.-B., additional, Aubin, F., additional, Ferrier-Le Bouedec, M.-C., additional, Du Thanh, A., additional, Raison-Peyron, N., additional, Walter-Lepage, A., additional, Lasek, A., additional, Schoeffler, A., additional, Lacour, J.-P., additional, Misery, L., additional, Richard, M.-A., additional, Droitcourt, C., additional, DIllies, A.-S., additional, Soria, A., additional, Delaunay, J., additional, Rappelle-Duruy, S., additional, Bellon, N., additional, Barete, S., additional, Mahé, E., additional, Begon, E., additional, Valois, A., additional, Dompmartin-Blanchère, A., additional, Morice, C., additional, Beneton, N., additional, Barbarot, S., additional, Seneschal, J., additional, and Staumont-Sallé, D., additional

Published
2018
Full Text
View/download PDF

225. Neurofibromatose 1 : recommandations de prise en charge

Author

Pinson, S, Créange, A, Barbarot, S, Stalder, J.F, Chaix, Y, Rodriguez, D, Sanson, M, Bernheim, A, d’Incan, M, Doz, F, Stoll, C, Combemale, P, Kalifa, C, Zeller, J, Teillac-Hamel, D, Lyonnet, S, Zerah, M, Lacour, J.P, Guillot, B, and Wolkenstein, P

Published
2002
Full Text
View/download PDF

226. Ivermectine 400 vs 200μg/kg en association avec la perméthrine 5 % pour le traitement de la gale sévère (profuse et hyperkératosique) : essai contrôlé randomisé multicentrique

Author

Do-Pham, G., Bernigaud, C., Guichard, E., Beylot-Barry, M., Goujon, E., Isnard, C., Beneton, N., Tedbirt, B., Samimi, M., Michel, C., Adamski, H., Perrot, J.L., Mahé, E., Azib, S., Chaby, G., Passeron, T., Acquitter, M., Vanhaecke, C., Burstzejn, A.C., Caux, F., Mahé, A., Leccia, M.T., Barbarot, S., Lenormand, C., Aubin, F., Gregoire, L., Giraudeau, B., and Chosidow, O.

Abstract

Le traitement de la gale sévère, mal codifié et parfois sous-optimal, n’a jamais fait l’objet d’un essai contrôlé randomisé (ECR). Les experts préconisent l’association traitement local – ivermectine orale à dose standard et administrée de façon répétée. Des doses plus élevées d’ivermectine ont permis d’accroître son efficacité dans certaines parasitoses (pédiculose du cuir chevelu notamment). Le but de l’essai était de comparer 2 doses d’ivermectine, 400 vs 200μg/kg, dans la gale sévère.

Published
2023
Full Text
View/download PDF

227. Gale commune de l’enfant et de l’adulte : comparaison de la perméthrine topique à 5 % à l’ivermectine orale 200μg/kg administrées à 2 reprises. Essai contrôlé randomisé en cluster avec évaluateur en insu

Author

Boralevi, F., Simon, G., Miraglia, J., Bernigaud, C., Brun, J., Perrot, J.L., Goujon, E., Phan, A., Herissé, A.L., Maruani, A., Vanhaecke, C., Couty, E., Mallet, S., Abasq-Thomas, C., Hubiche, T., Brenaut, E., Caux, F., Beneton, N., Aubert, H., Bourrat, E., Adamski, H., Miquel, J., Loget, J., Janela, R., Couzan, C., Eyraud, A., Marti, A., Duong, T.A., Bonniaud, B., Barbarot, S., Dinulescu, M., Lebidre, E., Leducq, S., Monestier, S., Seneschal, J., Etienne, M., Huet, F., Delion, F., Morice-Picard, F., Léauté-Labrèze, C., Capelli, A., Giraudeau, B., and Chosidow, O.

Abstract

Dans la gale commune, les traitements recommandés (Cochrane, sociétés savantes…) sont la perméthrine topique (PER) et l’ivermectine orale (IVM) mais les données comparatives à l’échelon individuel sont de niveau de preuve faible. En outre, aucun essai en cluster n’a été mené alors que l’enjeu du traitement de la gale commune est de traiter systématiquement le patient et les membres de son entourage proche (premier cercle). L’objectif principal de cet essai contrôlé randomisé (ECR) en cluster était de comparer PER vs IVM dans la gale commune.

Published
2023
Full Text
View/download PDF

228. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Author

Chalmers, J. R., Thomas, K. S., Apfelbacher, C., Williams, H. C., Prinsen, C. A., Spuls, P. I., Simpson, E., Gerbens, L. A. A., Boers, M., Barbarot, S., Stalder, J. F., Abuabara, K., Aoki, V., Ardeleanu, M., Armstrong, J., Bang, B., Berents, T. L., Burton, T., Butler, L., Chubachi, T., Cresswell-Melville, A., DeLozier, A., Eckert, L., Eichenfield, L., Flohr, C., Futamura, M., Gadkari, A., Gjerde, E. S., van Halewijn, K. F., Hawkes, C., Howells, L., Howie, L., Humphreys, R., Ishii, H. A., Kataoka, Y., Katayama, I., Kouwenhoven, W., Langan, S. M., Leshem, Y. A., Merhand, S., Mina-Osorio, P., Murota, H., Nakahara, T., Nunes, F. P., Nygaard, U., Nygardas, M., Ohya, Y., Ono, E., Rehbinder, E., Rogers, N. K., Romeijn, G. L. E., Schuttelaar, M. L. A., Sears, A. V., Simpson, M. A., Singh, J. A., Srour, J., Stuart, B., Svensson, A., Talmo, G., Talmo, H., Teixeira, H. D., Thyssen, J. P., Todd, G., Torchet, F., Volke, A., von Kobyletzki, Laura B., Weisshaar, E., Wollenberg, A., Zaniboni, M., Chalmers, J. R., Thomas, K. S., Apfelbacher, C., Williams, H. C., Prinsen, C. A., Spuls, P. I., Simpson, E., Gerbens, L. A. A., Boers, M., Barbarot, S., Stalder, J. F., Abuabara, K., Aoki, V., Ardeleanu, M., Armstrong, J., Bang, B., Berents, T. L., Burton, T., Butler, L., Chubachi, T., Cresswell-Melville, A., DeLozier, A., Eckert, L., Eichenfield, L., Flohr, C., Futamura, M., Gadkari, A., Gjerde, E. S., van Halewijn, K. F., Hawkes, C., Howells, L., Howie, L., Humphreys, R., Ishii, H. A., Kataoka, Y., Katayama, I., Kouwenhoven, W., Langan, S. M., Leshem, Y. A., Merhand, S., Mina-Osorio, P., Murota, H., Nakahara, T., Nunes, F. P., Nygaard, U., Nygardas, M., Ohya, Y., Ono, E., Rehbinder, E., Rogers, N. K., Romeijn, G. L. E., Schuttelaar, M. L. A., Sears, A. V., Simpson, M. A., Singh, J. A., Srour, J., Stuart, B., Svensson, A., Talmo, G., Talmo, H., Teixeira, H. D., Thyssen, J. P., Todd, G., Torchet, F., Volke, A., von Kobyletzki, Laura B., Weisshaar, E., Wollenberg, A., and Zaniboni, M.

Abstract

This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12-14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Moderated whole-group and small-group consensus discussions were informed by presentations of qualitative studies, systematic reviews and validation studies. Small-group allocations were performed a priori to ensure that each group included different stakeholders from a variety of geographical regions. Anonymous whole-group voting was carried out using handheld electronic voting pads according to pre-defined consensus rules. It was agreed by consensus that the long-term control domain should include signs, symptoms, quality of life and a patient global instrument. The group agreed that itch intensity should be measured when assessing long-term control of eczema in addition to the frequency of itch captured by the symptoms domain. There was no recommendation of an instrument for the core outcome domain of quality of life in children, but existing instruments were assessed for face validity and feasibility, and future work that will facilitate the recommendation of an instrument was agreed upon.

Published
2018
Full Text
View/download PDF

229. Klinisch bedeutsame und signifikante Verbesserung von Krankheitszeichen, Symptomen und Lebensqualität unter Dupilumab bei Patienten mit atopischer Dermatitis ohne Erreichen von IGA 0 oder 1: eine Post-hoc-Analyse der LIBERTY AD SOLO-Studien

Author

Simpson E, L, Silverberg J, I, Thaçi, D, Barbarot, S, Bagel, J, Chen, Z, Chao, J, Graham N M, H, Pirozzi, G, Ardeleanu, M, Simpson E, L, Silverberg J, I, Thaçi, D, Barbarot, S, Bagel, J, Chen, Z, Chao, J, Graham N M, H, Pirozzi, G, and Ardeleanu, M

Published
2018

230. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Author

Chalmers, JR, Thomas, KS, Apfelbacher, C, Williams, HC, Prinsen, CA, Spuls, PI, Simpson, E, Gerbens, LAA, Boers, M, Barbarot, S, Stalder, JF, Abuabara, K, Aoki, V, Ardeleanu, M, Armstrong, J, Bang, B, Berents, TL, Burton, T, Butler, L, Chubachi, T, Cresswell-Melville, A, DeLozier, A, Eckert, L, Eichenfield, L, Flohr, C, Futamura, M, Gadkari, A, Gjerde, ES, Halewijn, Karlijn, Hawkes, C, Howells, L, Howie, L, Humphreys, R, Ishii, HA, Kataoka, Y, Katayama, I, Kouwenhoven, W, Langan, SM, Leshem, YA, Merhand, S, Mina-Osorio, P, Murota, H, Nakahara, T, Nunes, FP, Nygaard, U, Nygardas, M, Ohya, Y, Ono, E, Rehbinder, E, Rogers, NK, Romeijn, GLE, Schuttelaar, MLA, Sears, AV, Simpson, MA, Singh, JA, Srour, J, Stuart, B, Svensson, A, Talmo, G, Talmo, H, Teixeira, HD, Thyssen, JP, Todd, G, Torchet, F, Volke, A, von Kobyletzki, L, Weisshaar, E, Wollenberg, A, Zaniboni, M, Chalmers, JR, Thomas, KS, Apfelbacher, C, Williams, HC, Prinsen, CA, Spuls, PI, Simpson, E, Gerbens, LAA, Boers, M, Barbarot, S, Stalder, JF, Abuabara, K, Aoki, V, Ardeleanu, M, Armstrong, J, Bang, B, Berents, TL, Burton, T, Butler, L, Chubachi, T, Cresswell-Melville, A, DeLozier, A, Eckert, L, Eichenfield, L, Flohr, C, Futamura, M, Gadkari, A, Gjerde, ES, Halewijn, Karlijn, Hawkes, C, Howells, L, Howie, L, Humphreys, R, Ishii, HA, Kataoka, Y, Katayama, I, Kouwenhoven, W, Langan, SM, Leshem, YA, Merhand, S, Mina-Osorio, P, Murota, H, Nakahara, T, Nunes, FP, Nygaard, U, Nygardas, M, Ohya, Y, Ono, E, Rehbinder, E, Rogers, NK, Romeijn, GLE, Schuttelaar, MLA, Sears, AV, Simpson, MA, Singh, JA, Srour, J, Stuart, B, Svensson, A, Talmo, G, Talmo, H, Teixeira, HD, Thyssen, JP, Todd, G, Torchet, F, Volke, A, von Kobyletzki, L, Weisshaar, E, Wollenberg, A, and Zaniboni, M

Published
2018

231. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

Author

Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J.P., Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M.J., Kunz, B., Fölster‐Holst, R., Trzeciak, M., Darsow, U., Szalai, Z., Deleuran, M., Kobyletzki, L., Barbarot, S., Heratizadeh, A., and Gieler, U.

Subjects
ATOPIC dermatitis, ECZEMA, TASK forces, COAL tar, DISEASE exacerbation, ANTI-inflammatory agents
Abstract

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient's age and also target flare prevention. Basic therapy includes hydrating and barrier‐stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti‐inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid‐potency corticosteroids are proven agents for proactive therapy, which is defined as the long‐term intermittent anti‐inflammatory therapy of frequently relapsing skin areas. Systemic anti‐inflammatory or immunosuppressive treatment is a rapidly changing field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit–risk ratio. The IL‐4R‐blocker dupilumab is a safe, effective and licensed, but expensive, treatment option with potential ocular side‐effects. Other biologicals targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R‐blockers) only have limited effects on AD‐related itch and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be useful for atopic hand and foot eczema. Dietary recommendations should be patient‐specific, and elimination diets should only be advised in case of proven food allergy. Allergen‐specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress‐induced exacerbations. Efficacy‐proven 'Eczema school' educational programmes and therapeutic patient education are recommended for both children and adults. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

233. Effect of antenatal maternal supplementation with GOS/inulin prebiotics on atopic dermatitis in high-risk children (PREGRALL): Study protocol for a randomized controlled trial

Author

Bodinier, Marie, Coudol, S., Legrand, A., Planche, L., Bouchaud, Grégory, Winer, Norbert, Dochez, Vincent, Riochet, D., Aubert, H., Barbarot, S., Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de la Recherche Agronomique (INRA), Centre Hospitalier Universiatire Hôtel-Dieu de Nantes (CHU Hôtel-Dieu), Centre de Recherche en Nutrition Humaine, and ProdInra, Migration

Subjects
[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process Engineering, [SDV.IDA]Life Sciences [q-bio]/Food engineering, [SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering, [SDV.IDA] Life Sciences [q-bio]/Food engineering, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

234. P14.33 Adult brainstem gliomas in neurofibromatosis type 1 (NF1)

Author

Pierre Wolkenstein, Luc Bauchet, François Ducray, Florence Laigle-Donadey, Jean-Sébastien Guillamo, Wang A, Barbarot S, O Chinot, and D. Frappaz

Subjects
Cancer Research, Pathology, medicine.medical_specialty, business.industry, medicine.disease, nervous system diseases, Poster Presentations, Text mining, Oncology, medicine, Neurology (clinical), Brainstem, Neurofibromatosis, business, neoplasms
Abstract

BACKGROUND The brainstem is the second location of brain tumors after optic pathways in NF1. In NF1 children, brainstem gliomas are usually indolent and have a better prognosis than their counterparts in non NF1 children. In contrast, the natural history and prognosis of adult brainstem gliomas in NF1 are nearly unknown. MATERIAL AND METHODS We conducted a retrospective analysis of medical records and MRI of adult NF1 patients followed for a brainstem glioma in 8 centers over a 17 years period (2000–2017). Clinical and imaging characteristics, management and outcome were analyzed. RESULTS Twenty five patients were included in the study (13 males and 12 females) with a median age of 32 (range 17–58). The epicenter of the tumor was located into the pons n=13 (52%), the mesencephalon n=7 (28%), the medulla oblongata n=5 (20%). On MRI, contrast enhancement was seen in 19 tumors (76%). Pathological examination was available in 13 tumors (52%) and showed a high grade astrocytoma (III or IV) in 9 tumors. Five patients were asymptomatic, 3 remained asymptomatic during the follow-up (median follow-up: 86 months, range 22–124). Twenty patients were symptomatic with a median duration of symptom of 2.5 months (range 1–10) before diagnosis. Among these symptomatic patients, 15 died from tumor progression despite treatment with radiation therapy and or chemotherapy. The median overall survival of symptomatic patients was 36 months. CONCLUSION Brainstem gliomas are rare tumors in adults with NF1. Unlike children, adult brainstem gliomas seem to have an unexpected poor prognosis, suggesting the disease may be different in adulthood.

Published
2019

236. Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing*.

Author

Le Cleach, L., Dousset, L., Assier, H., Fourati, S., Barbarot, S., Boulard, C., Bourseau Quetier, C., Cambon, L., Cazanave, C, Colin, A., Kostrzewa, E., Lesort, C., Levy Roy, A., Lombart, F., Marco‐Bonnet, J., Monfort, J.‐B., Samimi, M., Tardieu, M., Wolkenstein, P., and Sbidian, E.

Subjects
COVID-19 pandemic, COVID-19, REVERSE transcriptase polymerase chain reaction, POLYMERASE chain reaction
Abstract

Summary: Background: Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID‐19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2 when performed, and serology was generally not performed. Methods: A national survey was launched on 30 March 2020 by the French Society of Dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID‐19 by using a standardized questionnaire. We report the results for acral manifestations. Results: We collected 311 cases of acral manifestations [58.5% women, median age 25.7 years (range 18–39)]. The most frequent clinical presentation (65%) was typical chilblains. In total, 93 cases (30%) showed clinical suspicion of COVID‐19, 67 (22%) had only less specific infectious symptoms and 151 (49%) had no clinical signs preceding or during the course of acral lesions. Histology of skin biopsies was consistent with chilblains. Overall, 12 patients showed significant immunological abnormalities. Of the 150 (48%) patients who were tested, 10 patients were positive. Seven of 121 (6%) RT‐PCR‐tested patients were positive for SARS‐CoV‐2, and five of 75 (7%) serology‐tested patients had IgG anti‐SARS‐CoV‐2. Tested/untested patients or those with/without confirmed COVID‐19 did not differ in age, sex, history or acral lesion clinical characteristics. Conclusions: The results of this survey do not rule out that SARS‐CoV‐2 could be directly responsible for some cases of chilblains, but we found no evidence of SARS‐CoV‐2 infection in the large majority of patients with acral lesions during the COVID‐19 lockdown period in France. What is already known about this topic? About 1000 cases of acral lesions, mainly chilblains, were reported during the COVID‐19 outbreak.Chilblains were reported to occur in young people within 2 weeks of infectious signs, which were mild when present.Most cases did not have COVID‐19 confirmed by reverse transcription polymerase chain reaction (RT‐PCR), and few serology results were available. What does this study add? Among 311 patients with acral lesions, mainly chilblains, during the COVID‐19 lockdown period in France, the majority of patients tested had no evidence of SARS‐CoV‐2 infection.Overall, 70 of 75 patients were seronegative for SARS‐Cov‐2 serology and 114 of 121 patients were negative for SARS‐CoV‐2 RT‐PCR. What is already known about this topic? About 1000 cases of acral lesions, mainly chilblains, were reported during the COVID‐19 outbreak.Chilblains were reported to occur in young people within 2 weeks of infectious signs, which were mild when present.Most cases did not have COVID‐19 confirmed by reverse transcription polymerase chain reaction (RT‐PCR), and few serology results were available. What does this study add? Among 311 patients with acral lesions, mainly chilblains, during the COVID‐19 lockdown period in France, the majority of patients tested had no evidence of SARS‐CoV‐2 infection.Overall, 70 of 75 patients were seronegative for SARS‐Cov‐2 serology and 114 of 121 patients were negative for SARS‐CoV‐2 RT‐PCR. Plain language summary available online [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

237. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.

Author

Bosma, A.L., Spuls, P.I., Garcia‐Doval, I., Naldi, L., Prieto‐Merino, D., Tesch, F., Apfelbacher, C.J., Arents, B.W.M., Barbarot, S., Baselga, E., Deleuran, M., Eichenfield, L.F., Gerbens, L.A.A., Irvine, A.D., Manca, A., Mendes‐Bastos, P., Middelkamp‐Hup, M.A., Roberts, A., Seneschal, J., and Svensson, Å.

Subjects
ATOPIC dermatitis, SKIN cancer, LICENSE agreements, SPECIAL events, ADVERSE health care events, LONGITUDINAL method
Abstract

Summary: Background: A long‐term prospective observational safety study is essential to characterize fully the safety profile of systemic immunomodulating therapies for patients with atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a large platform to conduct such research using national registries that collect the same data using a predefined core dataset. Objectives: To present a protocol for a safety study comparing dupilumab with other systemic immunomodulating therapies in children and adults with moderate‐to‐severe atopic eczema, to assess the long‐term safety risk of these therapies in a routine clinical care setting. Methods: We describe a registry‐embedded international observational prospective cohort study. Adult and paediatric patients who start treatment with dupilumab or another systemic immunomodulating agent for their atopic eczema will be included. The primary end point is the incidence of malignancies (excluding nonmelanoma skin cancer) compared between the treatment groups. Secondary end points include other serious adverse events and adverse events of special interest, such as eye disorders and eosinophilia. Conclusions: This protocol delineates a safety study for dupilumab in adult and paediatric patients with atopic eczema, using a standardized methodological approach across several national registries. The protocol could also be used for other novel systemic immunomodulating therapies, and could provide licensing and reimbursement authorities, pharmaceutical companies and clinicians with safety evidence from a routine clinical care setting. What's already known about this topic? There is a need for long‐term data on the safety of systemic immunomodulating therapies in patients with atopic eczema.Regulatory bodies, such as the European Medicines Agency, increasingly stipulate the collection of such data as part of the licensing agreement for new treatments, to assess the new agent's long‐term safety profile against established therapies.Large numbers of patients with a long duration of follow‐up are necessary in order to detect rare events like malignancies. What does this study add? The TREAT Registry Taskforce offers a platform to conduct such research with a network of multiple national atopic eczema research registries.We present a protocol for an investigator‐initiated multicentre safety study comparing dupilumab with other systemic immunomodulating therapies in adults and subsequently adolescents and children with moderate‐to‐severe atopic eczema.This protocol can be used as a framework for similar studies for other novel systemic immunomodulating therapies across both adult and paediatric populations. Plain language summary available online [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

238. Tongue psoriasis: Clinical aspects and analysis of epidemiological associations in 313 children, with a systematic literature review

Author

Pourchot, D., primary, Chiaverini, C., additional, Bourrat, E., additional, Barbarot, S., additional, Vabres, P., additional, Hubiche, T., additional, Droicourt, C., additional, Piram, M., additional, Kupfer-Bessaguet, I., additional, Ferneiny, M., additional, Puzenat, E., additional, Balguérie, X., additional, Beauchet, A., additional, Bursztejn, A.-C., additional, and Mahé, E., additional

Published
2018
Full Text
View/download PDF

241. Search for RASA1 Variants in Capillary Malformations of the Legs in 113 Children: Results from the French National Paediatric Cohort CONAPE

Author

Maruani, A, primary, Durieux-Verde, M, additional, Mazereeuw-Hautier, J, additional, Boccara, O, additional, Martin, L, additional, Chiaverini, C, additional, Eschard, C, additional, Bénéton, N, additional, Vabres, P, additional, Balguerie, X, additional, Plantin, P, additional, Bessis, D, additional, Barbarot, S, additional, Dadban, A, additional, Droitcourt, C, additional, Berthelot, A, additional, Lorette, G, additional, Leducq, S, additional, Samimi, M, additional, Andres, C, additional, Caille, A, additional, and Dermatologie, P, additional

Published
2018
Full Text
View/download PDF

244. Harmonisation des registres de patients atteints d’eczéma atopique nécessitant un traitement systémique. Étude internationale de consensus

Author

Gerbens, L.A., primary, Apfelbacher, C., additional, Irvine, A.D., additional, Barbarot, S., additional, de Booij, R.J., additional, Boyce, A.E., additional, Deleuran, M., additional, Eichenfield, L.F., additional, Hof, M.H., additional, Middelkamp-Hup, M.A., additional, Roberts, A., additional, Schmitt, J., additional, Vestergaard, C., additional, Wall, D., additional, Weidinger, S., additional, Williamson, P.R., additional, Flohr, C., additional, and Spuls, P.I., additional

Published
2017
Full Text
View/download PDF

245. Psoriasis lingual. Aspects cliniques et analyse des associations épidémiologiques chez 313 enfants, et revue systématique de la littérature

Author

Pourchot, D., primary, Chiaverini, C., additional, Bourrat, E., additional, Barbarot, S., additional, Vabres, P., additional, Hubiche, T., additional, Droitcourt, C., additional, Piram, M., additional, Kupfer, I.-B., additional, Ferneiny, M., additional, Puzenat, E., additional, Balguerie, X., additional, Beauchet, A., additional, and Mahé, E., additional

Published
2017
Full Text
View/download PDF

246. Pyoderma gangrenosum et syndrome de Sweet pédiatriques : étude rétrospective multicentrique

Author

Bucchia, M., primary, Barbarot, S., additional, Meinzer, U., additional, Wallach, D., additional, Piram, M., additional, Begon, E., additional, Mahe, E., additional, Balguerie, X., additional, Mallet, S., additional, Phan, A., additional, Jean, S., additional, Reumaux, H., additional, Hatchuel, Y., additional, Merlin, E., additional, Decramer, S., additional, Lacour, J.P., additional, and Bourrat, E., additional

Published
2017
Full Text
View/download PDF

247. Caractéristiques clinicobiologiques, facteurs pronostiques et prise en charge thérapeutique du scléromyxœdème : étude rétrospective multicentrique

Author

Mahevas, T., primary, Jachiet, M., additional, Servy, A., additional, Livideanu, C. Bulai, additional, Cribier, B., additional, Frances, C., additional, Le Moigne, M., additional, Sbidian, E., additional, Bouaziz, J.-D., additional, Descamps, V., additional, D’incan, M., additional, Humbert, P., additional, Beylot-Barry, M., additional, Passeron, T., additional, Arnulf, B., additional, Harel, S., additional, Sassolas, B., additional, de Moreuil, C., additional, Hermine, O., additional, Dupuy, A., additional, Barbarot, S., additional, Debardieux, S., additional, Carpentier, O., additional, Brault, F., additional, Schmutz, J.-L., additional, Thomas-Beaulieu, D., additional, Zarnitsky, C., additional, Limal, N., additional, Le-Bras, F., additional, Osio, A., additional, Battistella, M., additional, Tauber, M., additional, Mékinian, A., additional, and Fain, O., additional

Published
2017
Full Text
View/download PDF

248. Œdème cyanique chronique douloureux des doigts

Author

Soenen, A., primary, Durant, C., additional, Aubert, H., additional, Guitteny, M., additional, Bougouin, E. Kuhn, additional, Penhoat, M. Gahier, additional, Kassam, D., additional, Bailly, C., additional, and Barbarot, S., additional

Published
2017
Full Text
View/download PDF

250. Facteurs associés au choix du premier traitement biologique dans le psoriasis. Résultats de la cohorte nationale PsoBioTeq

Author

Sbidian, E., primary, Giboin, C., additional, Bachelez, H., additional, Paul, C., additional, Beylot-Barry, M., additional, Dupuy, A., additional, Viguier, M., additional, Lacour, J.P., additional, Schmutz, J.L., additional, Bravard, P., additional, Mahé, E., additional, Beneton, N., additional, Misery, L., additional, Delaporte, E., additional, Modiano, P., additional, Barbarot, S., additional, Régnier, S., additional, Jullien, D., additional, Richard, M.A., additional, Joly, P., additional, Tubach, F., additional, and Chosidow, O., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results